Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy

Ye, Dezhuang; Chen, Si; Chen, Hong

doi:10.3389/fphy.2021.636985

Cited by 10 publications

(11 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite ultrasound being known to be a noisy imaging modality compared to various Ultrasound-Based AI for COVID-19 Detection other imaging modalities with exceptional image quality (i.e., CT, magnetic resonance imaging (MRI), X-ray, etc.) (Park et al, 2020), it stands out for being a low-cost, mobile, and, above all, non-ionizing medical imaging technology (Yuan et al, 2021). Because ultrasound is radiation-safe, it is the preferred imaging modality for children and pregnant women (Prentice et al, 2022) and has been widely used in the detection and severity assessment of COVID-19 for the same patient group (Allinovi et al, 2020).…”

Section: Ultrasound In Covid-2019 Diagnosismentioning

confidence: 99%

Ultrasound-Based AI for COVID-19 Detection: A Comprehensive Review of Public and Private Lung Ultrasound Datasets and Studies

Morshed¹,

Shihab²,

Jahin³

et al. 2023

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic has affected millions of people globally, with respiratory organs being strongly affected in individuals with comorbidities. Medical imaging-based diagnosis and prognosis have become increasingly popular in clinical settings to detect COVID-19 lung infections. Among various medical imaging modalities, ultrasound stands out as low-cost, mobile, and radiation-safe imaging technology. In this comprehensive review, we focus on ultrasound-based AI studies for COVID-19 detection that use public or private lung ultrasound datasets. We surveyed articles that used publicly available lung ultrasound datasets for COVID-19 and reviewed publicly available datasets and organize ultrasound-based AI studies per dataset. We analyzed and tabulated studies in several dimensions, such as data preprocessing, AI models, cross-validation, and evaluation criteria. In total, we reviewed 42 articles, where 28 articles used public datasets, and the rest used private data. Our findings suggest that ultrasound-based AI studies for the detection of COVID-19 have great potential for clinical use, especially for children and pregnant women. Our review also provides a useful summary for future researchers and clinicians who may be interested in the field.

show abstract

Section: Ultrasound In Covid-2019 Diagnosismentioning

confidence: 99%

Ultrasound-Based AI for COVID-19 Detection: A Comprehensive Review of Public and Private Lung Ultrasound Datasets and Studies

Morshed¹,

Shihab²,

Jahin³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…explicitly mentioned. In non-neurological conditions, FUS+MB exposure has been shown to stimulate immune responses that may be beneficial (e.g., in metastatic cancer) or directly induce anti-inflammatory effects at the target site [82][83][84][85]. Recent studies have also shown that immunomodulation can be successfully used to treat GBM, and that FUS+MBs can be effective in inducing targeted immune effects and in delivering immunotherapeutics with promising results [86,87].…”

Section: Trends In Neurosciencesmentioning

confidence: 99%

Neuroinflammation associated with ultrasound-mediated permeabilization of the blood–brain barrier

Jung

Thomas

Burks

et al. 2022

Trends in Neurosciences

View full text Add to dashboard Cite

“…While there has been a significant and deserved emphasis on focused ultrasound to transiently permeabilize the blood–brain barrier, ablative ultrasound therapies can also enhance immune checkpoint inhibition [ 188 ]. Thermal ablative ultrasound therapy uses high-intensity focused ultrasound to increase the local temperature to 60 °C or higher to induce coagulative necrosis.…”

Section: Strategies To Enhance Immunotherapy’s Effectivenessmentioning

confidence: 99%

Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers

Lechpammer

Rao

Shah

et al. 2022

Cancers

View full text Add to dashboard Cite

Glioblastoma, or glioblastoma multiforme (GBM, WHO Grade IV), is a highly aggressive adult glioma. Despite extensive efforts to improve treatment, the current standard-of-care (SOC) regimen, which consists of maximal resection, radiotherapy, and temozolomide (TMZ), achieves only a 12–15 month survival. The clinical improvements achieved through immunotherapy in several extracranial solid tumors, including non-small-cell lung cancer, melanoma, and non-Hodgkin lymphoma, inspired investigations to pursue various immunotherapeutic interventions in adult glioblastoma patients. Despite some encouraging reports from preclinical and early-stage clinical trials, none of the tested agents have been convincing in Phase III clinical trials. One, but not the only, factor that is accountable for the slow progress is the blood–brain barrier, which prevents most antitumor drugs from reaching the target in appreciable amounts. Herein, we review the current state of immunotherapy in glioblastoma and discuss the significant challenges that prevent advancement. We also provide thoughts on steps that may be taken to remediate these challenges, including the application of ultrasound technologies.

show abstract

Therapeutic Ultrasound-Enhanced Immune Checkpoint Inhibitor Therapy

Cited by 10 publications

References 58 publications

Ultrasound-Based AI for COVID-19 Detection: A Comprehensive Review of Public and Private Lung Ultrasound Datasets and Studies

Ultrasound-Based AI for COVID-19 Detection: A Comprehensive Review of Public and Private Lung Ultrasound Datasets and Studies

Neuroinflammation associated with ultrasound-mediated permeabilization of the blood–brain barrier

Advances in Immunotherapy for the Treatment of Adult Glioblastoma: Overcoming Chemical and Physical Barriers

Contact Info

Product

Resources

About